Boston Scientific Corporation News

BOSTON SCIENTIFIC CORPORATION: Boston Scientific to Participate in 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference

Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 in New York City.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Announces Recommended Offer to Acquire BTG plc.

Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals.

BOSTON SCIENTIFIC CORPORATION: WATCHMAN™ Wins Best Medical Technology Award

The Boston Scientific WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device has received the Prix Galien USA 2018 Award for Best Medical Technology.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Prevails in German Edwards Lifesciences Litigation

Boston Scientific Corporation (NYSE: BSX) today announced the District Court of Dusseldorf, Germany has determined that Edwards Lifesciences Corporation's Sapien 3 Ultra™ device infringed a patent – established by Symetis SA, a subsidiary of Boston Scientific – specific to the fabric used on the valve seal, specifically the German part of European Patent (EP) 2 949 292 B1.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Closes Acquisition of Augmenix, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR® Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.

Metro Business Network